GILD
Gilead Sciences Inc
NASDAQ: GILD · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$130.84
+1.55% today
Updated 2026-04-30
Market cap
$159.92B
P/E ratio
19.00
P/S ratio
5.43x
EPS (TTM)
$6.78
Dividend yield
2.44%
52W range
$93 – $156
Volume
6.1M
Gilead Sciences Inc (GILD) Financial statements
SEC filings — annual and quarterly data.
Profit margin
28.90%
Operating margin
37.40%
ROE
40.70%
ROA
12.50%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $3.03B | $-1.19B | 85.68% | -25.07% | -39.32% |
| 2007 | $4.23B | $1.62B | 81.83% | 51.17% | 38.19% |
| 2008 | $5.34B | $1.98B | 78.87% | 50.20% | 37.09% |
| 2009 | $7.01B | $2.64B | 77.24% | 50.34% | 37.59% |
| 2010 | $7.95B | $2.90B | 76.48% | 49.84% | 36.50% |
| 2011 | $8.39B | $2.80B | 74.67% | 45.20% | 33.43% |
| 2012 | $9.70B | $2.59B | 74.53% | 41.33% | 26.72% |
| 2013 | $11.20B | $3.08B | 74.48% | 40.39% | 27.45% |
| 2014 | $24.89B | $12.10B | 84.78% | 61.33% | 48.62% |
| 2015 | $32.64B | $18.11B | 87.73% | 68.00% | 55.48% |
| 2016 | $30.39B | $13.50B | 85.98% | 58.02% | 44.43% |
| 2017 | $26.11B | $4.63B | 83.26% | 54.10% | 17.73% |
| 2018 | $22.13B | $5.46B | 78.07% | 37.06% | 24.65% |
| 2019 | $22.45B | $5.39B | 79.18% | 19.10% | 23.99% |
| 2020 | $24.69B | $123.00M | 81.48% | 16.49% | 0.50% |
| 2021 | $27.30B | $6.22B | 75.82% | 36.32% | 22.80% |
| 2022 | $27.28B | $4.59B | 79.26% | 26.87% | 16.83% |
| 2023 | $27.12B | $5.67B | 100.00% | 28.05% | 20.89% |
| 2024 | $28.75B | $480.00M | 78.26% | 5.78% | 1.67% |
| 2025 | $29.44B | $8.51B | 86.69% | 40.14% | 28.90% |